Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 81% Improvement Relative Risk Improvement 44% Ventilation 51% c19early.org/cp Bar et al. NCT04397757 PennCCP2 Conv. Plasma RCT LATE Favors conv. plasma Favors control
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia
Bar et al., Journal of Clinical Investigation, doi:10.1172/JCI155114, PennCCP2, NCT04397757 (history)
Bar et al., A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia, Journal of Clinical Investigation, doi:10.1172/JCI155114, PennCCP2, NCT04397757
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 79 hospitalized patients in the USA, showing significant benefit in clinical severity score and 28-day mortality with convalescent plasma treatment.
risk of death, 81.0% lower, HR 0.19, p = 0.03, treatment 40, control 39, Cox proportional hazards, day 28.
risk of no improvement, 43.8% lower, OR 0.56, p = 0.18, treatment 40, control 39, WHO8 score, day 28, RR approximated with OR.
risk of mechanical ventilation, 51.2% lower, RR 0.49, p = 0.16, treatment 5 of 40 (12.5%), control 10 of 39 (25.6%), NNT 7.6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bar et al., 15 Dec 2021, Randomized Controlled Trial, USA, peer-reviewed, median age 63.0, 40 authors, study period 18 May, 2020 - 8 January, 2021, trial NCT04397757 (history) (PennCCP2).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: The Journal of Clinical Investigation   CLINICAL MEDICINE A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia Katharine J. Bar,1 Pamela A. Shaw,1,2 Grace H. Choi,1 Nicole Aqui,1 Andrew Fesnak,1 Jasper B. Yang,1,2 Haideliza Soto-Calderon,1 Lizette Grajales,1 Julie Starr,1 Michelle Andronov,1 Miranda Mastellone,1 Chigozie Amonu,1 Geoff Feret,1 Maureen DeMarshall,1 Marie Buchanan,1 Maria Caturla,1 James Gordon,1 Alan Wanicur,1 M. Alexandra Monroy,1 Felicity Mampe,1 Emily Lindemuth,1 Sigrid Gouma,1 Anne M. Mullin,1 Holly Barilla,1 Anastasiya Pronina,1 Leah Irwin,1 Raeann Thomas,1 Risa A. Eichinger,1 Faye Demuth,1 Eline T. Luning Prak,1 Jose L. Pascual,1 William R. Short,1 Michal A. Elovitz,1 Jillian Baron,1 Nuala J. Meyer,1 Kathleen O. Degnan,1 Ian Frank,1 Scott E. Hensley,1 Donald L. Siegel,1 and Pablo Tebas1 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2Kaiser Permanente Washington Health Research Group, Seattle, Washington, USA. 1 BACKGROUND. Antibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients with pneumonia are limited. Here, we assess the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia. METHODS. We performed a randomized control trial (PennCCP2), with 80 adults hospitalized with COVID-19 pneumonia, comparing up to 2 units of locally sourced CCP plus standard care versus standard care alone. The primary efficacy endpoint was comparison of a clinical severity score. Key secondary outcomes include 14- and 28-day mortality, 14- and 28-day maximum 8-point WHO ordinal score (WHO8) score, duration of supplemental oxygenation or mechanical ventilation, respiratory SARS-CoV-2 RNA, and anti–SARS-CoV-2 antibodies. RESULTS. Eighty hospitalized adults with confirmed COVID-19 pneumonia were enrolled at median day 6 of symptoms and day 1 of hospitalization; 60% were anti–SARS-CoV-2 antibody seronegative. Participants had a median of 3 comorbidities, including risk factors for severe COVID-19 and immunosuppression. CCP treatment was safe and conferred significant benefit by clinical severity score (median [MED] and interquartile range [IQR] 10 [5.5–30] vs. 7 [2.75–12.25], P = 0.037) and 28-day mortality (n = 10, 26% vs. n = 2, 5%; P = 0.013). All other prespecified outcome measures showed weak evidence toward benefit of CCP. CONCLUSION. Two units of locally sourced CCP administered early in hospitalization to majority seronegative participants conferred a significant benefit in clinical severity score and 28-day mortality. Results suggest CCP may benefit select populations, especially those with comorbidities who are treated early. TRIAL REGISTRATION. ClinicalTrials.gov NCT04397757. FUNDING. University of Pennsylvania.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit